NCT01461083View on ClinicalTrials.gov

Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

May 31, 2014

Conditions
Parkinson Disease
Interventions
DRUG

[18F]MPPF

Subjects will be dosed by intravenous bolus injection of \[18F\]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not \>10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF

Trial Locations (1)

06510

Molecular NeuroImaging, LLC, New Haven

All Listed Sponsors
lead

Institute for Neurodegenerative Disorders

OTHER

NCT01461083 - Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a | Biotech Hunter | Biotech Hunter